Vasomedical, a developer of technologies to treat cardio vascular diseases, has received the US Food and Drug Administration (FDA) approval for its BIOX Model 1303 3-channel ECG Holter Monitor and Model 1304 12-channel ECG Holter Monitor.
The BIOX models are used to record and analyze ECG and blood pressure data which provide information about incidental cardiovascular abnormalities to clinicians for various diagnostic needs.
Vasomedical claims the newly cleared ultra compact Model 1303 ECG Holter Monitor is lightest with an LCD display for viewing of recorded information.
Vasomedical-BIOX series monitors work with the FDA cleared CB Series analysis software.
Vasomedical’s BIOX brand ambulatory monitoring products include the 1300 Series ECG Holter monitors, 1800 Series ambulatory BP monitors and 2300 Series combined ECG Holter/ABP monitors.
Vasomedical president and CEO Jun Ma said together with its technology of Enhanced External Counterpulsation (EECP) therapy systems, the company has positioned itself for growth as a solutions partner to the cardiac marketplace that demands the best in products, technology and support.